Gland Pharma Q1 FY27 Results Analysis: PAT Jumps 47%, EBITDA Margin Expands 300 bps

Gland Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,800.27 Cr (+19.57% YoY) and PAT growth of +47.09% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Gland Pharma delivered a record Q1 with 19.6% YoY revenue growth and 47% PAT growth, driven by strong US market performance and CDMO expansion. EBITDA margin expanded 300 bps YoY. Post-quarter, the Sugammadex launch provides a near-term catalyst. However, subsidiary losses and raw material cost headwinds in coming quarters temper the outlook.

Key Investment Insights

Key Positives

• Revenue grew 19.57% YoY to Rs.1,800.27 Cr, a record Q1
• PAT grew 47.09% YoY to Rs.316.96 Cr, outpacing revenue growth
• EBITDA margin expanded 300 bps YoY to 27.4%
• CDMO segment grew 20.29% YoY, reaching 49.5% share of revenue
• US market revenue grew 31.80% YoY, driven by volume and new launches
• Post-quarter, Sugammadex received USFDA approval with Day-1 launch
• Net cash position of Rs.3,116 Cr provides balance sheet strength

Risk Factors

• Subsidiary drag of Rs.47.43 Cr on consolidated PAT, indicating Cenexi still loss-making
• Raw material cost headwind expected in Q2-Q3 as inventory buffer depletes
• Canada, Australia & New Zealand market declined 27.74% YoY
• EBITDA margin compressed 200 bps QoQ from Q4 peak of 29.4%